New cancer chemotherapeutic agents

New chemotherapeutic agents for non-small cell lung cancer.

The identification of new chemotherapeutic agents for the treatment of non-small cell lung cancer should proceed in a structured, logical fashion. Agents should be evaluated on the basis of multiple objective and subjective end points. A 15% or greater major objective response rate, demonstrated in multiple single-agent phase II trials, is considered the lower limit for an agent to be deemed cl...

Oral chemotherapeutic agents for colorectal cancer.

A number of novel oral chemotherapeutic agents are entering practice or are under development in the United States. Many of these agents display significant clinical activity against colorectal cancer. Many classes of compounds, including fluoropyrimidine analogs, dihydropyrimidine dehydrogenase (DPD) inhibitors, topoisomerase inhibitors, farnesyl transferase inhibitors, and others, are being d...

Evaluation of Chemotherapeutic Agents

This fourth, thoroughly revised, edition of Calmette's well-known manual aims to bring together the maximum of information which will be of value to the bacteriologist in his daily work. It is based largely on the techniques utilized at the Pasteur Institute in Paris. The topics included differ from those found in similar manuals in this country which are usually texts of laboratory diagnosis a...

Enzymes as Chemotherapeutic Agents

New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.

Non-small cell lung cancer (NSCLC) is refractory to systemic chemotherapy, compared with small cell lung cancer. Until recently, only five drugs--cisplatin, vindesine, mitomycin, ifosfamide, and vinblastine--could produce overall response rates of 15% against NSCLC. However, recent efforts have contributed to the development of new drugs with activity against NSCLC, including irinotecan hydroch...